Modified Del Nido Cardioplegia with a 1:4 Crystalloid-to-Blood Ratio Versus Blood-Based St. Thomas Cardioplegia in Isolated Aortic Valve Replacement
Journal of Cardiovascular Development and Disease · 11.06.2026 · 13 (6) · 263
DOI: 10.3390/jcdd13060263 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Cardiovascular Development and Disease, online erschienen am 11.06.2026. Verfasst von Peter Jakub und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Heart Surgery, East Slovak Institute for Cardiovascular Diseases and Medical Faculty, Pavol Jozef Šafárik University, 04011 Košice, Slo…. Die Arbeit nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
The aim of this study was to retrospectively compare modified Del Nido and blood-based St. Thomas cardioplegia in adult patients undergoing isolated aortic valve replacement (AVR). This retrospective study included adult patients undergoing isolated AVR because of aortic valve stenosis between 2024 and 2025. Patients were stratified into blood-based St. Thomas and modified Del Nido groups. The main modification of the Del Nido solution was the adjustment of the crystalloid-to-blood ratio to 1:4. Preoperative and perioperative variables, as well as postoperative biomarkers, including high-sensitivity troponin I, creatine kinase (CK), CK-MB, and lactate, were analyzed. A total of 93 patients were included in the study (blood-based St. Thomas: n = 22; modified Del Nido: n = 71). No significant differences were observed in cardiopulmonary bypass time [98 min (IQR 84–110) vs. 90 min (IQR 74–110); p = 0.184] or aortic cross-clamp time [75 min (IQR 67–86) vs. 73 min (IQR 62–87); p = 0.345]. High-sensitivity troponin I levels at 24 h were numerically, but not statistically significantly, lower in the blood-based St. Thomas group [1961 ng/L (IQR 1367–4423) vs. 2819 ng/L (IQR 1698–5054); p = 0.240]. CK levels at 6 h were comparable between the groups [8.4 μkat/L (IQR 6.5–10.1) vs. 8.5 μkat/L (IQR 6.0–12.7); p = 0.632], as were CK-MB and lactate levels at all evaluated time points. In exploratory multivariable analyses adjusted for age, sex, preoperative LVEF, cardiopulmonary bypass time, and aortic cross-clamp time, cardioplegia type was not independently associated with postoperative biomarker levels. The less frequent dosing and membrane-stabilizing properties of modified Del Nido cardioplegia did not translate into statistically significant clinical or biochemical advantages in the setting of relatively short, isolated AVR procedures.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Heart Surgery, East Slovak Institute for Cardiovascular Diseases and Medical Faculty, Pavol Jozef Šafárik University, 04011 Košice, Slovakia.
ORCID-Profile: Tomáš Toporcer, Michal Trebišovský, Štefan Lukačín, Adrián Kolesár
Zitieren
APA
Jakub, P., Toporcer, T., Marcin, M., Trebišovský, M., Bereš, A., Homola, M., Lukačín, Š., & Kolesár, A. (2026). Modified Del Nido Cardioplegia with a 1:4 Crystalloid-to-Blood Ratio Versus Blood-Based St. Thomas Cardioplegia in Isolated Aortic Valve Replacement. Journal of Cardiovascular Development and Disease, 13(6), 263. https://doi.org/10.3390/jcdd13060263
Vancouver
Jakub P, Toporcer T, Marcin M, Trebišovský M, Bereš A, Homola M, et al. Modified Del Nido Cardioplegia with a 1:4 Crystalloid-to-Blood Ratio Versus Blood-Based St. Thomas Cardioplegia in Isolated Aortic Valve Replacement. Journal of Cardiovascular Development and Disease. 2026;13(6):263. doi:10.3390/jcdd13060263
BibTeX
@article{Jakub2026,
author = {Jakub, Peter and Toporcer, Tomáš and Marcin, Matúš and Trebišovský, Michal and Bereš, Anton and Homola, Marián and Lukačín, Štefan and Kolesár, Adrián},
title = {Modified Del Nido Cardioplegia with a 1:4 Crystalloid-to-Blood Ratio Versus Blood-Based St. Thomas Cardioplegia in Isolated Aortic Valve Replacement},
journal = {Journal of Cardiovascular Development and Disease},
year = {2026},
volume = {13},
number = {6},
pages = {263},
doi = {10.3390/jcdd13060263}
}
EUVIMED